Gilead withdraws bladder cancer drug in US
Gilead withdraws bladder cancer drug in US after failed trial
Gilead Sciences said on Friday it was voluntarily withdrawing its drug, Trodelvy, for patients with a type of bladder cancer after it failed to meet the main goal in a confirmatory trial. The decision was made in consultation with the U.
Gilead pulls Trodelvy's approval in bladder cancer after trial flop, FDA discussions
Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high NSCLC. Started in February 2023, the trial currently bears a primary completion date in January 2027.
Gilead Withdraws ADC Trodelvy in Bladder Cancer After Trial Failure
The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for bladder cancer in 2021, failed its confirmatory trial earlier this year.
Gilead withdraws Trodelvy in bladder cancer
The antibody drug conjugate didn’t help patients live longer in a confirmatory trial, prompting a review of its conditional approval in that indication.
Gilead Voluntarily Withdraws Urothelial Cancer Drug in US
(Reuters) - Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously treated patients with a type of urothelial cancer after consultation with the regulator. Copyright 2024 Thomson Reuters.
After Failed Confirmatory Trial, Gilead Withdraws US Accelerated Approval Of Trodelvy As Bladder Cancer treatment
Gilead Sciences is set to withdraw Trodelvy's accelerated approval for metastatic urothelial cancer following unsatisfactory results from the TROPiCS-04 study. However, the decision does not impact Trodelvy's other approved uses.
Drugmaker Pulls Trodelvy's Bladder Cancer Approval
Sacituzumab govitecan's (Trodelvy) accelerated approval in urothelial cancer will be voluntarily withdrawn, Gilead Sciences announced on Friday. The decision was made in consultation with the FDA and does not affect the antibody-drug conjugate's other indications, the company said.
ENDPOINTS NEWS1d
Gilead pulls Trodelvy's ac­cel­er­at­ed la­bel in blad­der can­cer af­ter drug failed con­fir­ma­to­ry study
Gilead is withdrawing the accelerated approval for its blockbuster antibody-drug conjugate Trodelvy for bladder cancer after ...
pharmaphorum4d
Gilead's Trodelvy approved in metastatic urothelial cancer
The US pharma hopes that the drug will be used in those patients ... have been withdrawn in bladder cancer as a result. Gilead said Trodelvy’s safety profile in the TROPHY study is consistent ...
Investor's Business Daily on MSN25d
AstraZeneca Stock Dips On Surprise Miss For Gilead-Rivaling Cancer Drug
Shares of Gilead Sciences, which has a rival ADC approved for this form of breast cancer closed roughly flat at 83.99.
Barron's17d
Gilead Licenses HIV-prevention Drug To Generic Drugmakers
The announcement comes shortly after Gilead faced pressure to open lenacapavir to a patent pool that would allow generics to be sold under license in those countries. The antiretroviral drug has ...